Spotlight on estradiol and norgestimate as hormone replacement therapy in postmenopausal women

Treatments in Endocrinology

Volumn 1, Issue 2, 2002, Pages 127-129

  Curran, Monique P ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NORETHISTERONE ACETATE; NORGESTIMATE;

ABDOMINAL PAIN; BONE MINERAL; BONE TURNOVER; BREAST CANCER; BREAST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DYSMENORRHEA; EDEMA; HEADACHE; HORMONE SUBSTITUTION; HUMAN; MASTALGIA; MENOPAUSAL SYNDROME; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; UTERUS BLEEDING; VAGINA ATROPHY; VASOMOTOR DISORDER;

CONTRACEPTIVES, ORAL, SYNTHETIC; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NORGESTREL; POSTMENOPAUSE;

EID: 0038345545     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201020-00006     Document Type: Review

References (11)

1. Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil 1996; 41: 16-21
2. Casper RF. Estrogen with interrupted progestin HRT: a review of experimental and clinical trials. Maturitas 2000; 34: 97-108
3. Rozenberg S. Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2001; 94: 86-91
4. Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous 17 β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000; 22 (5): 622-36
5. Lobo RA. Zacur HZ. Caubel P. et al. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17 β-estradiol on lipid and lipoprotein profiles. Am J Obstet Gynecol 2000; 182: 41-9
6. Prescribing information: Ortho-Prefest® (estradiol/norgestimate) tablets. Raritan (NJ): Ortho-McNeil Pharmaceutical Inc., 1999
7. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171-9
8. Corson SL, Richart RM, Caubel P, et al. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17 β-estradiol and norgestimate on endometrial histology. Int J Fertil 1999 Nov-Dec; 44: 279-85
9. Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil 1999; 44: 286-96
10. Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynecol Obstet 2001 Mar; 72: 235-43
11. Felsenberg D, van der Ouweland F, Friedman MD. Ortho-Prefest® for the prevention of bone loss in postmenopausal women [abstract no. 107]. North American Menopause Society 12th Annual Meeting; 2001 Oct 4-6; New Orleans